Abstract
The goal of medical management for benign prostatic hyperplasia (BPH) is to improve lower urinary tract symptoms (LUTS) of affected patients. Therapy is generally focused on mitigating the dynamic or static components of BPH pathophysiology. Alpha-adrenergic receptor blockers (alpha-blockers) are the most common first-line medication for BPH and function by inhibiting dynamic prostatic smooth muscle contraction to prevent bladder outlet obstruction. The medications in this class are equally effective and well tolerated, but medication side effects of hypotension, dizziness, and retrograde ejaculation determine specific medication selection for treatment. Androgen manipulation via 5 alpha-reductase inhibitors alleviates static components of LUTS by decreasing prostate size. This medication class can potentiate sexual side effects but has been shown to be extremely effective in conjunction with alpha-blockers. Phosphodiesterase inhibitors have demonstrated efficacy in treating men with BPH and coexisting erectile dysfunction, but their mechanism of improving LUTS is unclear. Anticholinergic and beta-3-agonist medications are indicated for patients with overactive bladder symptoms in the setting of BPH due to their ability to reduce detrusor spasms and increase bladder relaxation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attribbuted to benign prostatic hyperplasia: AUA guideline. Linthicum Heights: American Urology Association; 2018.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.
Miller DC, Saigal CS, Litwin MS. The demographic burden of urologic diseases in America. Urol Clin North Am. 2009;36(1):11–27.
Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975;47(2):193–202.
Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent areadensity of prostate smooth muscle. Prostate. 1992;21(4):297–307.
Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adenomas and the development of intravesical obstruction. Prostate. 1989;15(2):105–14.
James S, Chapple C, Phillips M, Greengrass P, Davey M, Turner-Warwick R, et al. Autoradiographic analysis of the alpha-adrenoreceptos and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol. 1989;142(2 Pt 1):438–44.
Forray C, Bard J, Wetzel J. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45:703–8.
Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, et al. Localization of endothelin receptors in the human prostate. J Urol. 1994;151(3):763–6.
Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50(7):551–4.
Ferrie B, Paterson P. Phenoxybenzamine in prostatic hypertrophy a double blind study. Br J Urol. 1987;59(1):63–5.
Ruutu M, Hansson E, Juusela H, Permi J, Rusk J, Sotarauta M, et al. Efficacy and side effects of prazosin as a symptomatic treatment of benign prostatic obstruction. Scand J Urol Nephrol. 1991;25(1):15–9.
Jardin A, Bensadoun H, Delauche-Cavallier M, Attatli P. Alfuzosin for benign prostatic hypertrophy. Lancet. 1991;338(8772):947.
Alabaster V, Davey M. The alpha 1-adrenoceptor antagonist profile of doxazosin; preclinical pharmacology. Br J Clin Pharmacol. 1986;21(Suppl 1):9S–17S.
Elliot H, Meredith P, Reid J. Pharmacokinetic overview of doxazosin. Am J Cardiol. 1987;59(14):78G–81G.
Sonders R. Pharmacokinetics of terazosin. Am J Med. 1986;80(5B):20–4.
Guay D. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004;2(1):14–23.
Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia United States 93-01 Study Group. J Urol. 1998;160:1701–6.
Ding H, Du W, Hou Z, Wang H, Wang Z. Silodosin is effective for treatment of LUTS in men with BPH: a systemic review. Asian J Androl. 2013;15(1):121–8.
Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld K, et al. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol. 2010;70(1):88–101.
Lepor H, Hill L. Sildosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010;30(12):1303–12.
Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, et al. The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia HYCAT Investigator Group. Urology. 1996;47(2):159–68.
Terazosin Abbot Laboratories. Hytrin (terazosin hydrochloride tablet) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf. Revised 07/2009. Accessed July 1, 2019.
Cr C, Carter P, Christmas TJ, Kriby RS, Bryan J, Milroy EJ, et al. A three month double blind study of doxazosinas treatment for benign prostatic obstruction. Br J Urol. 1994;74(1):50–6.
Fawzy A, Braun K, Lewis G, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154(1):105–9.
Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double blind, placebo-controlled, dose response multicenter study. J Urol. 1995;154(1):110–5.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bouedillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol. 1994;74(5):579–84.
Buzelin J, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol. 1997;31(2):190–8.
Van Kerrebroeck P, Jardin A, Laval K, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37(3):306–13.
Roerborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blinded, placebo-controlled studies. BJU Int. 2003;92(3):257–61.
Yamada S, Tanaka C, Kimua R, Kawabe K. Alpha 1-adrenoreceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci. 1994;54(24):1845–54.
Wilt T, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction; a systematic review of efficacy and adverse effects. J Urol. 2002;167(1):177–83.
Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Uses of an α1-Blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol. 1990;144(4):908–11.
Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective α1c-adrenoreceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76(3):325–36.
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51(6):892–900.
Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective α1A-adrenoreceptor antagonist, in patients with benign prostatic obstruction. BJU Int. 1997;80(4):587–96.
Chapple C, Wyndaele J, Nording J, Boeminghaus F, Ypma A, Abrams P. Tamsulosin, the first prostate-selective 1A-adrenoreceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155–67.
Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Sildosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl. 2013;15(1):121–8.
Kawabe K, Yoshida M, Homma Y. Silodosin. A new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active controlled clinical trial performed in Europe. Eur Urol. 2012;(5):38–42, 44–5.
Lepor H. Long term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology. 1995;45(3):406–13.
Van Dijk M, de la Rosette J, Michel M. Effects of alpha(1)-adrenoreceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.
Buzelin J, Fonteyne E, Kontturi M, Witjes WP, Khan A. Comparison of tamsulosin with alfuzosin in treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol. 1997;80(4):597–695.
Nordling J. Efficacy and safety of two doses (10mg and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005;95(7):1006–12.
Shakir S, Pearce G, Mann RD. Finesteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription event monitoring data. BJU Int. 2001;87:789–96.
Brookes S, Donovan J, Peters T, Abrams P, Neal D. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomized control trial. BMJ. 2002;324(7345):1059–61.
Hellstrom WJ, Smith W, Sikka SC. Effects of alpha blockers on ejaculatory function in normal subjects. J Urol. 2006;173(4 Pt 1):1529–33.
Chang D, Campbell J. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–73.
Wilson J. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980;68(5):745–56.
Siiteri P, Wilson J. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970;49(9):1737–45.
Moore R, Gazyk J, Quebbeman J, Wilson J. Concentration of dihydrotestosterone and 3a-androstanediol in naturally occurring and androgen induced prostatic hyperplasia in the dog. J Clin Invest. 1979;64(4):1003–10.
McConnell J. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate. 1990;17(S3):49–59.
Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5a-reductase in humans. Prostate. 1989;14(1):45–53.
Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol. 1998;11:393–422.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnel JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety study Group. N Engl J Med. 1998;228(9):557–63.
Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41.
Mocellini IA, Gardiner R, Marshall V, Johnson W, Bartsch G, Schmidbauer CP, et al. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993;22(4):291–9.
Marberger M. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology. 1998;51(5):677–86.
Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43(3):284–92; discussion 292-4.
Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrhorn C. Efficacy and safety of long-term treatment with dual 5-alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–94; discussion 495
Guess H, Heyse J, Gormley G. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22(1):31–7.
Wein A, Kavoussi L, Partin A, Peters C. Chapter 104, evaluation and nonsurgical management of benign prostatic hyperplasia. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.
Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of Dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.
Burnett A. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M–31M.
Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “aging male” symptoms? Results of the “Cologne male survey”. Eur Urol. 2003;44(5):588–94.
Blanker MH, Bohnen AM, Groeneveld FP, Bersen RM, Prins A, Thomas S, et al. Correlates for erectile dysfunction in older men: a community-based study. J Am Geriatr Soc. 2001;49(4):436–42.
Moreira ED, Lbo CF, Diament A, Nicolsi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61(2):431–6.
Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfuntion in four centers: the UrEpik study. BJU Int. 2003;92(7):719–25.
Brookes S, Link C, Donovan J, McKinlay J. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey. J Urol. 2008;179(1):250–5.
Sairam K, Kulinskaya E, McNicholas T, Boustead G, Hanbury D. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836–9.
McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7.
Roehrboen C, McVary K, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia; a dose finding study. J Urol. 2008;180(4):1228–34.
Porst H, Oekle M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and safety of tadalifil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analysis of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82(3):667–73.
Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2012;61(5):994–1003.
McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Slidenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trail. J Urol. 2007;177(3):1071–7.
Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in helathy subjects. Br J Clin Pharmacol. 2006;61(3):280–8.
Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 2010;106:674–80.
Thomas A, Abrams P. Lower urinary tract symptoms benign prostatic obstruction, and the overactive bladder. BJU Int. 2000;85(3):57–68.
Abrams P. Detrusor instability and bladder outlet obstruction. Neurourol Urodyn. 1985;4(4):317–28.
Speakerman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosing JA. Bladder outflow obstruction—a cause of denervation super sensitivity. J Urol. 1987;136(6):1461–6.
Greenland J, Brading A. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165:245.
Elbadawi A, Yalla S, Resnick N. Structural basis for geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150(5 Pt 2):1668–80.
Abramov Y, Sand P. Oxybutynon for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother. 2004;5(11):2351–9.
Elterman D, Kaplan S, Barkin J. Tolterodine for treatment of urge incontinence. Expert Opin Pharmacother. 2013;14(14):1987–91.
Blake-James B, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systemic review and meta-analysis. BJU Int. 2007;99(1):85–96.
Martin-Merino E, Garcia Rodriguez L, Masso Gonzales E, Roehrborn C. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009;182(4):1442–8.
Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in management of overactive bladder. Ther Adv Urol. 2012;288:1367–73.
Suarez O, Osborn D, Kaufman M, Reynolds WS, Dmochowski R. Curr Urol Rep. 2013;14(6):580–4.
Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, et al. Absorption, metabolism and excretion of (14)mirabegron (YM178), a potent and selective β(3)-adrenoreceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–24.
Chapple C, Cardozo L, Victor W, Nitti V, Siddiqui E, Michel M. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.
Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, et al. Proarrythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double blind placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706.
Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milson I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.
Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.
Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double blind, parallel-group, placebo-controlled, multicenter study to assess the efficacy and safety of β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.
Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gromley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med. 1996;335(8):533–9.
Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–26.
Debruyne FMJ, Jardin A, Colloi D, Resel L, Wities WPJ, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, Finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 1998;34(3):169–75.
McConnell JD, Roehrborn C, Bautista O, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long term effect of doxazosin, finasteride and combination theraopy on clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.
Kaplan SA, Roehrborn CG, Rovner ES, Carisson M, Bavendam T, Gaun Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28.
Kaplan SA, Walmsely K, Te A. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–6.
Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. BJU Int. 2004;94:817–20.
Kaplan S, Roehrborn C, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109(12):1831–40.
Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, et al. Efficacy and safety of solifenacin pluc tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64(3):398–407.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Showalter, V.C., Raynor, M.C. (2020). Medical Management of Benign Prostatic Hyperplasia. In: Isaacson, A., Bagla, S., Raynor, M., Yu, H. (eds) Prostatic Artery Embolization. Springer, Cham. https://doi.org/10.1007/978-3-030-23471-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-23471-3_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23470-6
Online ISBN: 978-3-030-23471-3
eBook Packages: MedicineMedicine (R0)